ERBB2 and neoplasm: In order to close this gap, in this study, we aimed to characterise the HER2 status evolution with the disease progression, by comparing it between the primary tumour and a matched recurrence (local recurrence or distant metastasis), as well as to identify possible clinical and pathological factors associated with these changes.